Plain language summary of the ZUMA-7 trial comparing axicabtagene ciloleucel to standard care for relapsed or refractory large B-cell lymphoma

This Plain Language Summary of Publication article (PLSP) from Future Oncology, highlights how axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy, compares with standard treatment for large B-cell lymphoma (LBCL), a cancer affecting B cells. Axi-cel, made from a patient’s own immune cells, leverages the body’s natural defences to target and fight cancer.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma’ and ‘Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma’ and were both published in the New England Journal of Medicine.

Visit NEJM using the link to read the original article.

Visit NEJM using the link to read the original article.

• Axi-cel
• Axicabtagene ciloleucel
• CAR T-cell therapy
• Hematologic/Lymphoma
• immunotherapy
• lay summary
• plain language summary
• ZUMA-7